AstraZeneca sets $4.5bn Virginia API plant construction in motion

AstraZeneca has commenced construction of its $4.5bn active pharmaceutical ingredient (API) manufacturing facility in Virginia. The site, which is located near Charlottesville, will produce APIs for medicines across its cardiovascular, obesity, oncology and metabolic disease portfolio. This includes drugs from the company’s mid-to-late-stage pipeline – namely its Eccogene-partnered glucagon-like peptide-1 receptor agonist (GLP-1RA) pill, AZD5004/ ECC-5004, as well as hypertension med baxdrostat and low-d ...